10-K Filing

ARROWHEAD PHARMACEUTICALS, INC. CIK: 879407 FY 2022

Filing Information

Form Type	10-K
Accession Number	`0001628280-22-030869`
Period End Date	20220930
Filing Date	20221128
Fiscal Year	2022
Fiscal Period	FY
XBRL Instance	arwr-20220930_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 74 Income Statement 57 Cash Flow Statement 83 Stockholders Equity 27

Balance Sheet 74 line items

Line Item	Tag	Value	Unit	Period
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, shares authorized (in shares)	`CommonStockSharesAuthorized`	145.00M	shares	Point-in-time
Common stock, shares authorized (in shares)	`CommonStockSharesAuthorized`	145.00M	shares	Point-in-time
Cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$184.43M	USD	Point-in-time
Cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$221.80M	USD	Point-in-time
Common stock, shares issued (in shares)	`CommonStockSharesIssued`	105.96M	shares	Point-in-time
Cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$143.58M	USD	Point-in-time
Cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$108.00M	USD	Point-in-time
Common stock, shares issued (in shares)	`CommonStockSharesIssued`	104.33M	shares	Point-in-time
Common stock, shares outstanding (in shares)	`CommonStockSharesOutstanding`	105.96M	shares	Point-in-time
Accounts receivable	`AccountsReceivableNetCurrent`	$10.26M	USD	Point-in-time
Common stock, shares outstanding (in shares)	`CommonStockSharesOutstanding`	104.33M	shares	Point-in-time
Accounts receivable	`AccountsReceivableNetCurrent`	$1.41M	USD	Point-in-time
Short-term investments	`HeldToMaturitySecuritiesCurrent`	$268.39M	USD	Point-in-time
Short-term investments	`HeldToMaturitySecuritiesCurrent`	$56.63M	USD	Point-in-time
Marketable securities	`MarketableSecuritiesCurrent`	-	USD	Point-in-time
Marketable securities	`MarketableSecuritiesCurrent`	$126.73M	USD	Point-in-time
Prepaid expenses	`PrepaidExpenseCurrent`	$7.29M	USD	Point-in-time
Prepaid expenses	`PrepaidExpenseCurrent`	$4.36M	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$2.19M	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$20.20M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$405.30M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$384.60M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$48.67M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$110.30M	USD	Point-in-time
Intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$13.66M	USD	Point-in-time
Intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$11.96M	USD	Point-in-time
Long-term investments	`HeldToMaturitySecuritiesNoncurrent`	$105.87M	USD	Point-in-time
Long-term investments	`HeldToMaturitySecuritiesNoncurrent`	$245.59M	USD	Point-in-time
Right-of-use assets	`OperatingLeaseRightOfUseAsset`	$58.29M	USD	Point-in-time
Right-of-use assets	`OperatingLeaseRightOfUseAsset`	$17.35M	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$272.00K	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$218.00K	USD	Point-in-time
Total Assets	`Assets`	$710.15M	USD	Point-in-time
Total Assets	`Assets`	$691.94M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$9.46M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$2.87M	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$14.00M	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$46.86M	USD	Point-in-time
Accrued payroll and benefits	`EmployeeRelatedLiabilitiesCurrent`	$12.25M	USD	Point-in-time
Accrued payroll and benefits	`EmployeeRelatedLiabilitiesCurrent`	$9.77M	USD	Point-in-time
Lease liabilities	`OperatingLeaseLiabilityCurrent`	$2.78M	USD	Point-in-time
Lease liabilities	`OperatingLeaseLiabilityCurrent`	$2.25M	USD	Point-in-time
Deferred revenue	`ContractWithCustomerLiabilityCurrent`	$111.06M	USD	Point-in-time
Deferred revenue	`ContractWithCustomerLiabilityCurrent`	$74.10M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$146.54M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$138.85M	USD	Point-in-time
Lease liabilities, net of current portion	`OperatingLeaseLiabilityNoncurrent`	$78.80M	USD	Point-in-time
Lease liabilities, net of current portion	`OperatingLeaseLiabilityNoncurrent`	$23.30M	USD	Point-in-time
Deferred revenue, net of current portion	`ContractWithCustomerLiabilityNoncurrent`	$55.95M	USD	Point-in-time
Deferred revenue, net of current portion	`ContractWithCustomerLiabilityNoncurrent`	$131.50M	USD	Point-in-time
Total long-term liabilities	`LiabilitiesNoncurrent`	$154.79M	USD	Point-in-time
Total long-term liabilities	`LiabilitiesNoncurrent`	$134.75M	USD	Point-in-time
Commitments and contingencies (Note 7)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies (Note 7)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Common stock, $0.001 par value: Authorized 145,000 shares; issued and outstanding 105,960 and 104,327 shares	`CommonStockValue`	$197.00K	USD	Point-in-time
Common stock, $0.001 par value: Authorized 145,000 shares; issued and outstanding 105,960 and 104,327 shares	`CommonStockValue`	$198.00K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapitalCommonStock`	$1.22B	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapitalCommonStock`	$1.05B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-69.00K	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-136.00K	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-644.69M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-820.75M	USD	Point-in-time
Total Arrowhead Pharmaceuticals, Inc. stockholders' equity	`StockholdersEquity`	$398.52M	USD	Point-in-time
Total Arrowhead Pharmaceuticals, Inc. stockholders' equity	`StockholdersEquity`	$408.82M	USD	Point-in-time
Noncontrolling interest	`MinorityInterest`	-	USD	Point-in-time
Noncontrolling interest	`MinorityInterest`	$19.82M	USD	Point-in-time
Total noncontrolling interest and stockholders' equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$244.04M	USD	Point-in-time
Total noncontrolling interest and stockholders' equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$418.34M	USD	Point-in-time
Total noncontrolling interest and stockholders' equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$408.82M	USD	Point-in-time
Total noncontrolling interest and stockholders' equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$461.78M	USD	Point-in-time
Total Liabilities, Noncontrolling Interest and Stockholders' Equity	`LiabilitiesAndStockholdersEquity`	$710.15M	USD	Point-in-time
Total Liabilities, Noncontrolling Interest and Stockholders' Equity	`LiabilitiesAndStockholdersEquity`	$691.94M	USD	Point-in-time

Income Statement 57 line items

Line Item	Tag	Value	Unit	Period
Revenue	`RevenueFromContractWithCustomerExcludingAssessedTax`	$138.29M	USD	Annual
Revenue	`RevenueFromContractWithCustomerExcludingAssessedTax`	$87.99M	USD	Annual
Revenue	`RevenueFromContractWithCustomerExcludingAssessedTax`	$243.23M	USD	Annual
Research and development	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$128.88M	USD	Annual
Research and development	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$297.31M	USD	Annual
Research and development	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$206.34M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$124.43M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$80.98M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$52.28M	USD	Annual
Total operating expenses	`OperatingExpenses`	$181.15M	USD	Annual
Total operating expenses	`OperatingExpenses`	$287.32M	USD	Annual
Total operating expenses	`OperatingExpenses`	$421.74M	USD	Annual
Operating loss	`OperatingIncomeLoss`	$-93.16M	USD	Annual
Operating loss	`OperatingIncomeLoss`	$-149.04M	USD	Annual
Operating loss	`OperatingIncomeLoss`	$-178.51M	USD	Annual
Interest income, net	`InterestIncomeExpenseNonoperatingNet`	$5.03M	USD	Annual
Interest income, net	`InterestIncomeExpenseNonoperatingNet`	$6.12M	USD	Annual
Interest income, net	`InterestIncomeExpenseNonoperatingNet`	$9.19M	USD	Annual
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$765.00K	USD	Annual
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$-583.00K	USD	Annual
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$2.07M	USD	Annual
Total other income	`NonoperatingIncomeExpense`	$8.19M	USD	Annual
Total other income	`NonoperatingIncomeExpense`	$8.61M	USD	Annual
Total other income	`NonoperatingIncomeExpense`	$5.80M	USD	Annual
Loss before income tax expense and noncontrolling interest	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-172.71M	USD	Annual
Loss before income tax expense and noncontrolling interest	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-84.55M	USD	Annual
Loss before income tax expense and noncontrolling interest	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-140.85M	USD	Annual
Income tax expense	`IncomeTaxExpenseBenefit`	$3.79M	USD	Annual
Income tax expense	`IncomeTaxExpenseBenefit`	$2.00K	USD	Annual
Income tax expense	`IncomeTaxExpenseBenefit`	$2.00K	USD	Annual
Net loss including noncontrolling interest	`ProfitLoss`	$-176.49M	USD	Annual
Net loss including noncontrolling interest	`ProfitLoss`	$-140.85M	USD	Annual
Net loss including noncontrolling interest	`ProfitLoss`	$-84.55M	USD	Annual
Net loss attributable to noncontrolling interest, net of tax	`NetIncomeLossAttributableToNoncontrollingInterest`	-	USD	Annual
Net loss attributable to noncontrolling interest, net of tax	`NetIncomeLossAttributableToNoncontrollingInterest`	-	USD	Annual
Net loss attributable to noncontrolling interest, net of tax	`NetIncomeLossAttributableToNoncontrollingInterest`	$-431.00K	USD	Annual
Net loss attributable to Arrowhead Pharmaceuticals, Inc.	`NetIncomeLoss`	$-176.06M	USD	Annual
Net loss attributable to Arrowhead Pharmaceuticals, Inc.	`NetIncomeLoss`	$-140.85M	USD	Annual
Net loss attributable to Arrowhead Pharmaceuticals, Inc.	`NetIncomeLoss`	$-84.55M	USD	Annual
Basic (in dollars per share)	`EarningsPerShareBasic`	$-1.67	USD	Annual
Basic (in dollars per share)	`EarningsPerShareBasic`	$-1.36	USD	Annual
Basic (in dollars per share)	`EarningsPerShareBasic`	$-0.84	USD	Annual
Diluted (in dollars per share)	`EarningsPerShareDiluted`	$-0.84	USD	Annual
Diluted (in dollars per share)	`EarningsPerShareDiluted`	$-1.67	USD	Annual
Diluted (in dollars per share)	`EarningsPerShareDiluted`	$-1.36	USD	Annual
Basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	103.75M	shares	Annual
Basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	100.72M	shares	Annual
Basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	105.43M	shares	Annual
Diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	103.75M	shares	Annual
Diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	105.43M	shares	Annual
Diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	100.72M	shares	Annual
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$410.00K	USD	Annual
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-87.00K	USD	Annual
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-67.00K	USD	Annual
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-84.14M	USD	Annual
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-176.56M	USD	Annual
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-140.94M	USD	Annual

Cash Flow Statement 83 line items

Line Item	Tag	Value	Unit	Period
Net loss including noncontrolling interest	`ProfitLoss`	$-176.49M	USD	Annual
Net loss including noncontrolling interest	`ProfitLoss`	$-140.85M	USD	Annual
Net loss including noncontrolling interest	`ProfitLoss`	$-84.55M	USD	Annual
Stock-based compensation	`ShareBasedCompensation`	$76.67M	USD	Annual
Stock-based compensation	`ShareBasedCompensation`	$43.38M	USD	Annual
Stock-based compensation	`ShareBasedCompensation`	$120.89M	USD	Annual
Net loss (gain) from investments	`GainLossOnInvestments`	$1.71M	USD	Annual
Net loss (gain) from investments	`GainLossOnInvestments`	$20.00K	USD	Annual
Net loss (gain) from investments	`GainLossOnInvestments`	$-4.43M	USD	Annual
Depreciation and amortization	`DepreciationAndAmortization`	$10.42M	USD	Annual
Depreciation and amortization	`DepreciationAndAmortization`	$8.27M	USD	Annual
Depreciation and amortization	`DepreciationAndAmortization`	$5.94M	USD	Annual
Amortization of note premiums	`InvestmentIncomeNetAmortizationOfDiscountAndPremium`	$-525.00K	USD	Annual
Amortization of note premiums	`InvestmentIncomeNetAmortizationOfDiscountAndPremium`	$-266.00K	USD	Annual
Amortization of note premiums	`InvestmentIncomeNetAmortizationOfDiscountAndPremium`	$-2.91M	USD	Annual
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$-8.85M	USD	Annual
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$9.41M	USD	Annual
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$184.00K	USD	Annual
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$19.29M	USD	Annual
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$387.00K	USD	Annual
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$360.00K	USD	Annual
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$-821.00K	USD	Annual
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$-6.59M	USD	Annual
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$2.63M	USD	Annual
Accrued expenses	`IncreaseDecreaseInAccruedLiabilities`	$9.52M	USD	Annual
Accrued expenses	`IncreaseDecreaseInAccruedLiabilities`	$1.99M	USD	Annual
Accrued expenses	`IncreaseDecreaseInAccruedLiabilities`	$17.75M	USD	Annual
Deferred revenue	`IncreaseDecreaseInContractWithCustomerLiability`	$-112.50M	USD	Annual
Deferred revenue	`IncreaseDecreaseInContractWithCustomerLiability`	$-63.51M	USD	Annual
Deferred revenue	`IncreaseDecreaseInContractWithCustomerLiability`	$223.26M	USD	Annual
Operating lease liabilities	`IncreaseDecreaseInOperatingLeaseLiability`	$3.19M	USD	Annual
Operating lease liabilities	`IncreaseDecreaseInOperatingLeaseLiability`	$1.12M	USD	Annual
Operating lease liabilities	`IncreaseDecreaseInOperatingLeaseLiability`	$13.43M	USD	Annual
Other	`IncreaseDecreaseInOtherOperatingLiabilities`	$-169.00K	USD	Annual
Other	`IncreaseDecreaseInOtherOperatingLiabilities`	$715.00K	USD	Annual
Other	`IncreaseDecreaseInOtherOperatingLiabilities`	$65.00K	USD	Annual
Net cash (used in) provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$171.31M	USD	Annual
Net cash (used in) provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-95.80M	USD	Annual
Net cash (used in) provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-136.13M	USD	Annual
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$11.95M	USD	Annual
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$52.78M	USD	Annual
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$23.57M	USD	Annual
Purchases of investments	`PaymentsToAcquireInvestments`	$278.96M	USD	Annual
Purchases of investments	`PaymentsToAcquireInvestments`	$223.39M	USD	Annual
Purchases of investments	`PaymentsToAcquireInvestments`	$240.70M	USD	Annual
Proceeds from sale of investments	`ProceedsFromSaleMaturityAndCollectionsOfInvestments`	$270.75M	USD	Annual
Proceeds from sale of investments	`ProceedsFromSaleMaturityAndCollectionsOfInvestments`	$122.59M	USD	Annual
Proceeds from sale of investments	`ProceedsFromSaleMaturityAndCollectionsOfInvestments`	$50.14M	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-141.68M	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-240.78M	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-5.42M	USD	Annual
Proceeds from the exercises of stock options	`ProceedsFromStockOptionsExercised`	$5.19M	USD	Annual
Proceeds from the exercises of stock options	`ProceedsFromStockOptionsExercised`	$11.30M	USD	Annual
Proceeds from the exercises of stock options	`ProceedsFromStockOptionsExercised`	$7.47M	USD	Annual
Proceeds from the issuance of common stock	`ProceedsFromIssuanceOfCommonStock`	-	USD	Annual
Proceeds from the issuance of common stock	`ProceedsFromIssuanceOfCommonStock`	$250.48M	USD	Annual
Proceeds from the issuance of common stock	`ProceedsFromIssuanceOfCommonStock`	-	USD	Annual
Proceeds from investment in joint venture	`ProceedsFromContributedCapital`	$60.00M	USD	Annual
Proceeds from investment in joint venture	`ProceedsFromContributedCapital`	-	USD	Annual
Proceeds from investment in joint venture	`ProceedsFromContributedCapital`	-	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$11.30M	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$257.95M	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$65.19M	USD	Annual
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect`	$40.94M	USD	Annual
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect`	$-76.36M	USD	Annual
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect`	$-78.63M	USD	Annual
EFFECT OF EXCHANGE RATE ON CASH AND CASH EQUIVALENTS	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$410.00K	USD	Annual
EFFECT OF EXCHANGE RATE ON CASH AND CASH EQUIVALENTS	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-67.00K	USD	Annual
EFFECT OF EXCHANGE RATE ON CASH AND CASH EQUIVALENTS	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-88.00K	USD	Annual
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$184.43M	USD	Point-in-time
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$221.80M	USD	Point-in-time
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$143.58M	USD	Point-in-time
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$108.00M	USD	Point-in-time
CASH AND CASH EQUIVALENTS AT END OF PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$184.43M	USD	Point-in-time
CASH AND CASH EQUIVALENTS AT END OF PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$221.80M	USD	Point-in-time
CASH AND CASH EQUIVALENTS AT END OF PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$143.58M	USD	Point-in-time
CASH AND CASH EQUIVALENTS AT END OF PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$108.00M	USD	Point-in-time
Interest paid	`InterestPaidNet`	-	USD	Annual
Interest paid	`InterestPaidNet`	-	USD	Annual
Interest paid	`InterestPaidNet`	-	USD	Annual
Income Taxes (Paid) Refunded	`IncomeTaxesPaidNet`	$103.00K	USD	Annual
Income Taxes (Paid) Refunded	`IncomeTaxesPaidNet`	$-2.00K	USD	Annual
Income Taxes (Paid) Refunded	`IncomeTaxesPaidNet`	$-2.00K	USD	Annual

Stockholders Equity 27 line items

Line Item	Tag	Value	Unit	Period
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$244.04M	USD	Point-in-time
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$418.34M	USD	Point-in-time
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$408.82M	USD	Point-in-time
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$461.78M	USD	Point-in-time
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$120.89M	USD	Annual
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$76.67M	USD	Annual
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$43.38M	USD	Annual
Exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$5.18M	USD	Annual
Exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$11.30M	USD	Annual
Exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$7.47M	USD	Annual
Exercise of stock options (in shares)	`StockIssuedDuringPeriodSharesStockOptionsExercised`	606,220.00	shares	Annual
Common stock - restricted stock units vesting	`StockIssuedDuringPeriodValueRestrictedStockAwardGross`	-	USD	Annual
Common stock - restricted stock units vesting	`StockIssuedDuringPeriodValueRestrictedStockAwardGross`	-	USD	Annual
Common stock - restricted stock units vesting	`StockIssuedDuringPeriodValueRestrictedStockAwardGross`	-	USD	Annual
Common stock - issued for cash	`StockIssuedDuringPeriodValueNewIssues`	$250.48M	USD	Annual
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$410.00K	USD	Annual
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-87.00K	USD	Annual
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-67.00K	USD	Annual
Deconsolidation of Ablaris Therapeutics, Inc.	`NoncontrollingInterestIncreaseFromDeconsolidation`	$555.00K	USD	Annual
Interest in joint venture	`NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance`	$60.00M	USD	Annual
Net loss	`ProfitLoss`	$-176.49M	USD	Annual
Net loss	`ProfitLoss`	$-140.85M	USD	Annual
Net loss	`ProfitLoss`	$-84.55M	USD	Annual
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$244.04M	USD	Point-in-time
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$418.34M	USD	Point-in-time
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$408.82M	USD	Point-in-time
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$461.78M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.